Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.</li>
<li>In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in December 2025.</li>
<li>We expect up to five ADDs and four DELs for the CSI Medical Service index during this index review event based on the latest available data.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
In this insight, we take a look at the potential ADDs and DELs leading the race for the semiannual index rebal event in December 2025.
We expect up to five ADDs and four DELs for the CSI Medical Service index during this index review event based on the latest available data.


Quiddity Leaderboard CSI Medical Dec25: US$300mn+ One-Way; Some Changes to Expectations

Beijing Strong Biotechnolo-A / Index Rebalance

<ul>
<li>We have already discussed our flow expectations for the mainstream indices in the CSI family such as CSI300/500, SSE50/100, and the STAR50/100 for the June 2024 index rebal event.</li>
<li>In this insight, we take a look at our flow expectations for the ADDs/DELs involved in the rebalance of some of the lesser known indices in the CSI family.</li>
<li>The indices covered in this insight are All Share Brokerage, China Internet, Medical Devices, National Defense, and Livestock Breeding indices.</li>
</ul>


We have already discussed our flow expectations for the mainstream indices in the CSI family such as CSI300/500, SSE50/100, and the STAR50/100 for the June 2024 index rebal event.
In this insight, we take a look at our flow expectations for the ADDs/DELs involved in the rebalance of some of the lesser known indices in the CSI family.
The indices covered in this insight are All Share Brokerage, China Internet, Medical Devices, National Defense, and Livestock Breeding indices.


CSI Esoteric Index Rebals Jun 24: All Share Brokerage, China Internet, Medical, Defense, & Livestock

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

<ul>
<li>CSI announced the changes for the June rebalance after market close on 31 May and the changes will be effective after the close of trading on 14 June.</li>
<li>There are 5 adds/deletes - we correctly forecasted 3 adds and all 5 deletes. Passives need to trade 0.5-3x ADV on the adds and 0.5-2.1x ADV on the deletes.</li>
<li>With the index not very widely forecasted, the adds could outperform the deletes over the next week in a repeat of the performance at the December rebalance.</li>
</ul>


CSI announced the changes for the June rebalance after market close on 31 May and the changes will be effective after the close of trading on 14 June.
There are 5 adds/deletes - we correctly forecasted 3 adds and all 5 deletes. Passives need to trade 0.5-3x ADV on the adds and 0.5-2.1x ADV on the deletes.
With the index not very widely forecasted, the adds could outperform the deletes over the next week in a repeat of the performance at the December rebalance.


CSI Medical Service Index Rebalance: Adds Could Outperform Deletes in the Coming Week

Shinva Medical Instrument A / Index Rebalance

<ul>
<li>The review period ended on 30 April, there are just over 2 weeks to announcement of the changes, and implementation will be done at the close on 14 June.</li>
<li>We forecast 5 potential changes for the index in June where there could be buying of 1.6-2.6x ADV on the adds and selling of 0.7-2.6x ADV on the deletes.</li>
<li>At the December 2023 rebalance, the adds outperformed the deletes in the weeks prior to announcement of the changes and then spiked post-announcement. Repeat this time?</li>
</ul>


The review period ended on 30 April, there are just over 2 weeks to announcement of the changes, and implementation will be done at the close on 14 June.
We forecast 5 potential changes for the index in June where there could be buying of 1.6-2.6x ADV on the adds and selling of 0.7-2.6x ADV on the deletes.
At the December 2023 rebalance, the adds outperformed the deletes in the weeks prior to announcement of the changes and then spiked post-announcement. Repeat this time?


CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains

APAC IPOs & Placements

Zhen Zhou, Toh

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<a href="https://www.smartkarma.com/entities/ivd-medical-holding-ltd" target="_blank" data-smartkarma-citation="entities:28143:1" rel="noopener">IVD Medical (1931 HK)</a> (IVDM) is looking to raise up to US$157m in its upcoming IPO.
IVDM is the result of the Original Group (Shanghai IVD distribution) acquiring Vastec (China Tier 1 IVD distributor) in January 2019. Overall, before the acquisition, both companies have been growing their revenue decently from FY16 - 18. ASP of Vastec's IVD reagents, which is the revenue driver, has also been increasing steadily.
However, the company did not provide sensible reason on why there was a need to engage an agent for the procurement of the IVD products from Sysmex and there were little disclosure surrounding these transactions. Furthermore, much of the IPO proceeds will not be used for expansion.

IVD Medical (1931 HK) (IVDM) is looking to raise up to US$157m in its upcoming IPO.
IVDM is the result of the Original Group (Shanghai IVD distribution) acquiring Vastec (China Tier 1 IVD distributor) in January 2019. Overall, before the acquisition, both companies have been growing their revenue decently from FY16 - 18. ASP of Vastec's IVD reagents, which is the revenue driver, has also been increasing steadily.
However, the company did not provide sensible reason on why there was a need to engage an agent for the procurement of the IVD products from Sysmex and there were little disclosure surrounding these transactions. Furthermore, much of the IPO proceeds will not be used for expansion.

IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition

China

Shinva Medical Instrument Co., Ltd. manufactures and markets medical instruments and equipment.  The Company's products include sterilization equipment, radiation diagnosis and radiotherapy equipment, chemical indication products, and medical environmental protection equipment.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shinva Medical Instrument A (600587 CH)

Quiddity Leaderboard CSI Medical Dec25: US$300mn+ One-Way; Some Changes to Expectations

We estimate the CSI Medical December 2025 index rebalance to trigger flows of ~US$308mn one-way. Most names have 1x-3x ADV to trade.

Janaghan Jeyakumar, CFA

CSI Medical Service Index Rebalance: Adds Could Outperform Deletes in the Coming Week

There are 5 changes for the index in June. We correctly forecast 3 adds and all 5 deletes. The adds outperformed the deletes post announcement in...

Brian Freitas

CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains

There could be 5 changes for the CSI Medical Service Index in June. Trackers will need to trade between 0.7-2.6x ADV. There was big outperformance...

Brian Freitas

IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition

IVD Medical (1931 HK) (IVDM) is looking to raise up to US$157m in its upcoming IPO. IVDM is the result of the Original Group (Shanghai IVD...

Zhen Zhou, Toh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Quiddity Leaderboard CSI Medical Dec25: US$300mn+ One-Way; Some Changes to Expectations

We estimate the CSI Medical December 2025 index rebalance to trigger flows of ~US$308mn one-way. Most names have 1x-3x ADV to trade.

Janaghan Jeyakumar, CFA

CSI Esoteric Index Rebals Jun 24: All Share Brokerage, China Internet, Medical, Defense, & Livestock

We expect the the CSI Medical Services ADDs to outperform the Medical Services DELs over the next few days. The Inclusion/Exclusion events could...

Janaghan Jeyakumar, CFA

CSI Medical Service Index Rebalance: Adds Could Outperform Deletes in the Coming Week

There are 5 changes for the index in June. We correctly forecast 3 adds and all 5 deletes. The adds outperformed the deletes post announcement in...

Brian Freitas

CSI Medical Service Index Rebalance Preview: Repeat of the December Rebal Could See Big Gains

There could be 5 changes for the CSI Medical Service Index in June. Trackers will need to trade between 0.7-2.6x ADV. There was big outperformance...

Brian Freitas

IVD Medical (華檢醫療) IPO Review - More than 70% of IPO Proceeds Used for Dividend and Acquisition

IVD Medical (1931 HK) (IVDM) is looking to raise up to US$157m in its upcoming IPO. IVDM is the result of the Original Group (Shanghai IVD...

Zhen Zhou, Toh